COPD, Asthma,ACO Clinical Trial
Official title:
Diagnostic Value of Sputum Cytology in Asthma-COPD Overlap
The aim of this study is to evaluate the diagnostic value of sputum cell counts in
differentiation between asthma, COPD and ACO.
to examine the relationship between sputum cell counts in bronchial revers¬ibility and
bronchial hyperresponsiveness
Asthma and COPD are considered as chronic airway inflammatory diseases, which are typically
associated with Th2-mediated immune response in asthma and related to the characteristics of
Th1-mediated immunity in COPD . Asthma-COPD overlap (ACO) is the term to describe patients
who have features of both asthma and COPD, recom¬mended by the 2019 Global Initiative for
Asthma (GINA) and the Global Initiative for Chronic Obstruction Lung Disease (GOLD)
guidelines. Patients with asthma and COPD are commonly seen in clinical practice. In
addition, compared with patients with asthma or COPD alone, patients with ACO experience
frequent exacerbations and hospitalizations, have poor quality of life, a more rapid decline
in lung function and high mortality, and consume a disproportionate amount of health care
resources than asthma or COPD alone .
Cell count in induced sputum is a noninvasive biomarker to assess airway inflammation
phenotypes. Accordingly, sputum cell counts are extensively used in the treatment of asthma
and COPD. Nevertheless, the clinical application of sputum cell counts in patients with
asthma-COPD overlap (ACO) remains elusive .
;